US 7,595,044 B2
	Artery-and vein-specific proteins and uses therefor
Hai U. Wang, Folsom, Calif. (US); Zhoufeng Chen, St. Louis, Mo. (US); and David J. Anderson, Altadena, Calif. (US)
Assigned to California Institute of Technology, Pasadena, Calif. (US)
Filed on Jan. 04, 2005, as Appl. No. 11/28,803.
Application 11/028803 is a continuation of application No. 09/687652, filed on Oct. 13, 2000, granted, now 6,887,674.
Application 09/687652 is a continuation in part of application No. PCT/US99/08098, filed on Apr. 13, 1999.
Application PCT/US99/08098 is a continuation in part of application No. 09/085820, filed on May 28, 1998, granted, now 6,864,227.
Application 09/085820 is a continuation in part of application No. 09/083546, filed on May 22, 1998, abandoned.
Claims priority of provisional application 60/081757, filed on Apr. 13, 1998.
Prior Publication US 2006/0288434 A1, Dec. 21, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 14/00 (2006.01); A61K 38/00 (2006.01)

U.S. Cl. 424—130.1  [424/140.1; 424/178.1; 514/2; 530/350]

8 Claims

1. A method for inhibiting angiogenesis in a mammal, comprising administering a therapeutically effective quantity of an antibody selected from the group consisting of: i) an antibody which specifically binds to EphriniB2; and ii) an antibody which binds to EphB4, wherein said antibody inhibits angiogenesis in an indicator mouse which comprises a reporter construct in a locus selected from the group consisting of the EphB4 locus and the EphB2 locus.